The Combination of the Selective Cyclooxygenase‐2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second‐Line Therapy for Non‐Small Cell Lung Cancer: A Phase II Study with Biological Correlates
暂无分享,去创建一个
L. Mariani | A. Avallone | G. Gasparini | S. Meo | M. Gion | G. Mansueto | T. Gamucci | G. Cornelia | P. Bonginelli | S. L. Vullo | D. Gattuso | S. Stani